Arbidol (umifenovir) / Pharmstandard - LARVOL DELTA

HFIP-Promoted Nenitzescu Indole Synthesis: An Application toward the Synthesis of Umifenovir. (PubMed, J Org Chem) - "The process demonstrates excellent functional-group tolerance and was successfully performed on a gram scale. Furthermore, the utility of this strategy is highlighted by the formal synthesis of a key intermediate for Umifenovir (Arbidol), highlighting its potential for industrial pharmaceutical applications."

Journal

Aqueous ozonation of the antiviral drug umifenovir (Arbidol): Reaction pathways and transformation products. (PubMed, Chemosphere) - "Umifenovir is rapidly removed from the reaction medium; however, persistent intermediate and deep transformation products remain even under excess ozonation. These findings highlight the need for advanced analytical methods for transformation product identification and for evaluating ozonation efficiency based on product formation rather than parent compound removal alone."

Journal

Pregnancy Outcomes After Maternal or Paternal Exposure to Etrasimod: An Updated Analysis From the Clinical Development Program (ACG 2026) - "[c]One patient had an anembryonic gestation where umifenovir (received for a respiratory tract infection) was a co-suspected drug. Of 2,665 unique patients exposed to etrasimod in the clinical program, 753 (28.3%) were women of childbearing age (16â44 years). A total of 24 pregnancies with etrasimod exposure were reported (13 maternal, 11 paternal). Women with maternal exposure were aged 18â37 years."

Clinical • Alopecia • Atopic Dermatitis • Crohn's disease • Dermatitis • Eosinophilic Esophagitis • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Long-acting Reversible Contraceptives • Respiratory Diseases • Ulcerative Colitis

On neighborhood degree sum-based indices of Nirmatrelvir and its QSPR investigation with some other COVID-19 drugs. (PubMed, In Silico Pharmacol) - "Furthermore, we present the QSPR analysis using curvilinear regression models among the obtained topological indices and physicochemical properties of the antiviral COVID-19 drugs, such as Molnupiravir, Arbidol, Chloroquine, Hydroxychloroquine, Thalidomide, Remdesivir, Ritonavir, Theaflavin and Lopinavir, including Nirmatrelvir. The results reveal that several considered indices show significant correlations with the physicochemical properties and cubic regression models consistently provide superior predictive accuracy. These findings demonstrate neighborhood degree sum-based topological indices as robust and reliable molecular descriptors in QSPR modelling, highlighting their significant potential for effective prediction of drug properties and their valuable role in facilitating rational drug design and development."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Critical updates in the 2024 influenza clinical practice guidelines of the World Health Organization. (PubMed, Infect Dis Immun) - "Baloxavir is not recommended for non-severe cases without severe risk factors, and other antivirals like oseltamivir, laninamivir, peramivir, zanamivir, favipiravir, and arbidol are not recommended for non-severe patients...Resource availability and co-infections can influence guideline implementation. Further research is needed to identify optimal strategies for specific populations."

Clinical guideline • Journal • Infectious Disease • Influenza • Obesity • Respiratory Diseases

Efficacy and Safety of Umifenovir (Arbidol) in Children with Influenza-like Illnesses: A Systematic Review and Meta-Analysis. (PubMed, Pediatr Rep) - " A comprehensive search of PubMed, Russian (RSCI, national archives, regulatory documents), and Chinese (CNKI) databases was conducted for pediatric randomized controlled trials (RCTs) and non-randomized trials comparing umifenovir to symptomatic therapy (ST) or oseltamivir. Umifenovir may reduce symptom duration, complications, and infection risk in pediatric ILI, with a favorable safety profile. However, the overall certainty of evidence is limited by the age of the studies, geographic restriction, and methodological quality."

Journal • Retrospective data • Review • Cough • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Development of a Water-soluble Form of Umifenovir Through the Synergistic Action of a Surfactant and a Hydrotropic Agent: A Multifactorial Study. (PubMed, Pharm Res) - "This study highlights the advantage of simultaneously using low concentrations of Brij35 and ChB to achieve a synergistic action for maximal improvement in UMF solubility with a minimal reduction in permeability."

Journal

Enhanced Antiviral Activity of Novel Umifenovir Derivatives against SARS-CoV-2: Insights from an International Collaborative Study. (PubMed, ACS Omega) - "Consistent with these findings, exploratory molecular docking results should be regarded as hypothesis-generating, suggesting a potential involvement of compound 11 in later viral entry events rather than in direct viral inactivation. These findings provide a foundation for advancing 11 as a hit compound for further optimization within antiviral strategies against SARS-CoV-2 variants."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Efficacy and safety of Toujie Quwen Granules in patients infected with SARS-CoV-2: A prospective cohort study of 156 cases. (PubMed, Chin Herb Med) - "The WM group received conventional WM treatment (antibiotics, glucocorticoids, oxygen therapy, arbidol, chloroquine, lopinavir/ ritonavir, ambroxol hydrochloride), while the TJQW + WM group received TJQW in addition to WM (15 g/bag, two bags at a time, three times a day). The TJQW + WM group showed a better improvement in symptoms and a reduction in the expression of inflammatory factors than the WM group. TJQW could effectively decrease the incidence of severe disease, reduce pulmonary inflammation and fibrosis, and alleviate clinical symptoms."

Journal • Fibrosis • Immunology • Infectious Disease • Inflammation • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Effects of Cytochrome P450 enzymes and drug-drug interaction on donafenib metabolism: in vivo, in vitro and in silico. (PubMed, Bioorg Chem) - "This study systematically elucidated the metabolic characteristics of the hepatocellular carcinoma (HCC) therapeutic drug donafenib and its drug-drug interaction (DDI) with the antiviral agent arbidol. Moreover, Tmax was prolonged by 68.42%, while CLz/F was decreased by 53.85%. These results provided critical references for clinical dosage adjustment, facilitating personalized treatment and reducing the risk of adverse reactions."

Journal • Preclinical • Hepatocellular Cancer • Oncology • Solid Tumor • CYP3A4

Umifenovir Protects Procambarus clarkii Against White Spot Syndrome Virus by Suppressing Viral Replication and Modulating Innate Immunity. (PubMed, Fish Shellfish Immunol) - "Collectively, these findings provide the first evidence that umifenovir exerts potent anti-WSSV activity in crustaceans by coordinately suppressing viral replication and modulating host immune responses, offering new mechanistic insights into its immunomodulatory effects. Given its favorable safety profile and feasibility for industrial synthesis, umifenovir represents a promising antiviral candidate for immunological intervention and provides a potential translational basis for future disease control strategies in aquaculture."

Journal • Immunology • Infectious Disease • Inflammation

A randomized, open, two-agent, single-dose postprandial bioequivalence trial of arbidol hydrochloride tablets in healthy subjects (ChiCTR) - P=N/A | N=48 | Completed | Sponsor: The Second Hospital of Hebei Medical University; The Second Hospital of Hebei Medical University

New trial

Antiviral strategies against H5N1: current options and emerging therapeutics. (PubMed, Infection) - "This article provides a comprehensive, up-to-date overview of antiviral agents with established or investigational activity against H5N1, including both globally approved drugs and regionally licensed compounds, such as arbidol and triazavirin in Russia and laninamivir and favipiravir in Japan...The recent regulatory approvals of onradivir, suraxavir marboxil, and ZX-7101A in China are highlighted, along with emerging antivirals in advanced development...Challenges persist around resistance monitoring, access to novel therapies, and regulatory harmonization. Expanding the antiviral armamentarium through accelerated evaluation and integration of both traditional and innovative compounds will be essential to pandemic preparedness and effective H5N1 outbreak response."

Journal • Review • Infectious Disease • Influenza • Respiratory Diseases

Discovery of a novel broad-spectrum inhibitor against influenza virus A. (PubMed, Virol J) - "Arbidol, an effective pharmaceutical against IAV and other viruses, inhibits viral fusion by targeting a conserved binding region across multiple virus types...The molecular structure of Glycyrrhetinic acid is more flexible, which avoids significant interactions with hERG. These findings highlight glycyrrhetinic acid as a promising broad-spectrum anti-IAV candidate drug."

Journal • Cardiovascular • Infectious Disease • Influenza • Respiratory Diseases

The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD. (clinicaltrials.gov) - P4 | N=351 | Completed | Sponsor: Shengjing Hospital | Enrolling by invitation ➔ Completed | N=990 ➔ 351

Enrollment change • Trial completion • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Mechanistic insights into the small-molecule inhibition of influenza A virus entry. (PubMed, Proc Natl Acad Sci U S A) - "Structure-guided mutagenesis confirmed the critical roles of key interacting residues and uncovered distinct resistance profiles between the two compounds, as well as in comparison to Arbidol, a previously reported HA inhibitor...To address this, we propose an alternative strategy for broadening antiviral coverage. Together, these findings provide mechanistic insights into IAV entry inhibition and a foundation for the rational design of next-generation anti-influenza therapeutics."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Bioequivalence of arbidol hydrochloride tablets in a randomized, open, two-agent, single-dose, three-cycle fasting trial in healthy subjects (ChiCTR) - P1 | N=36 | Completed | Sponsor: The Second Hospital of Hebei Medical University; The Second Hospital of Hebei Medical University

New P1 trial

Clinical Evaluation of Umifenovir as a Potential Antiviral Therapy for COVID-19: A Multi-center, Randomized, Controlled Clinical Trial. (PubMed, Oman Med J) - "While umifenovir exhibited some immunological benefits in COVID-19 patients, it did not significantly improve broader patient-important outcomes compared to standard care. Therefore, its routine use in clinical practice for COVID-19 treatment is currently not justified, highlighting the need for further research to explore alternative therapeutic strategies."

Clinical • Journal • Critical care • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Pain

Supercomputing Multi-Ligand Modeling, Simulation, Wavelet Analysis and Surface Plasmon Resonance to Develop Novel Combination Drugs: A Case Study of Arbidol and Baicalein Against Main Protease of SARS-CoV-2. (PubMed, Pharmaceuticals (Basel)) - " HQA004 demonstrated synergistic potential with arbidol in inhibiting Mpro. The development of combination therapies integrating Western and herbal medicine is supported by these findings for effective antiviral treatments."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

On degree-dependent topological study of line graph of some antiviral COVID-19 drugs. (PubMed, Eur Phys J E Soft Matter) - "This article focuses on the topological characterization of a line graph for antiviral COVID-19 drugs, namely Nirmatrelvir, Molnupiravir, Thalidomide, Theaflavin, Remdesivir, Ritonavir, Chloroquine, Hydroxychloroquine, Arbidol and Lopinavir. A comparison is made between the squared correlation coefficients derived from our curvilinear regression models and those obtained from earlier research. These findings may aid the applicability of newly developed drugs of similar kind, in predicting their physicochemical properties and in improving the associated QSPR studies and hence pave a way to improve treatments against the COVID-19 disease."

Journal • Infectious Disease • Novel Coronavirus Disease

Hemagglutinin docking analysis-based visual detection of antiviral therapeutic efficacy of umifenovir against influenza virus. (PubMed, Biosens Bioelectron) - "Additionally, the aggregation of umi-GNPs with viruses pre-bound to umifenovir was suppressed, indicating that umi-GNPs bind to a specific region of the viral protein. These findings indicate that umi-GNPs can serve as novel agents for visually determining umifenovir resistance in IAV."

Journal • Infectious Disease • Influenza • Respiratory Diseases

COVID-19 management in patients with comorbid conditions. (PubMed, World J Virol) - "Antiviral agents like Remdesivir, an adenosine nucleotide analog, inhibit viral RNA polymerase and have shown efficacy in reducing COVID-19 severity, leading to its emergency use authorization for hospitalized patients. Other antivirals like ritonavir, lopinavir, and umifenovir disrupt viral replication and entry, but their effectiveness against SARS-CoV-2 remains under investigation. Dexamethasone, a corticosteroid, has been used in critically ill COVID-19 patients to reduce inflammation and prevent respiratory failure, as shown in the RECOVERY trial. Other immunosuppressants like ruxolitinib, baricitinib, and colchicine help modulate the immune response, reducing cytokine storms and inflammation-related complications...Systematic reviews of clinical studies revealed that hydroxychloroquine with or without azithromycin did not decrease viral load nor reduce the severity of symptoms, but increased mortality among acutely hospitalized patients...Monoclonal antibodies like..."

Journal • Review • Acute Lung Injury • Acute Respiratory Distress Syndrome • Cardiovascular • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Diabetes • Ebola Virus Disease • Genetic Disorders • Heart Failure • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Obesity • Pulmonary Disease • Renal Disease • Respiratory Diseases

STAR: Severe Influenza Trial of ARbidol (clinicaltrials.gov) - P3 | N=200 | Completed | Sponsor: Capital Medical University | Unknown status ➔ Completed | Trial completion date: Aug 2020 ➔ Oct 2024

Trial completion • Trial completion date • Infectious Disease • Influenza • Respiratory Diseases

Antiviral therapy for influenza in high-risk outpatients: a multicenter observational study of routine clinical practice in Russia. (PubMed, Ther Adv Infect Dis) - "The study was conducted during the 2023-2024 influenza epidemic season and included 1867 high-risk outpatients treated with oseltamivir, umifenovir, kagocel, or imidazolyl ethanamide pentanedioic acid. The etiotropic agents oseltamivir and umifenovir demonstrated comparable efficacy in managing influenza in high-risk patients, as reflected by their impact on bacterial complication rates and disease duration. Both drugs may be recommended for the treatment of high-risk influenza patients."

Journal • Observational data • Allergy • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Influenza • Respiratory Diseases

Antimicrobial Prescribing Patterns in Russian Outpatients in 2024: Results of the Global-PPS Project. (PubMed, Infect Chemother) - "The pooled rates of antimicrobial prescribing in outpatient settings was 9.6% with the substantial differences in patterns of consumption overall and among the units of different types. Broad-spectrum antibacterials such as penicillin/beta-lactamase inhibitor combinations, III-IV generation cephalosporins, fluoroquinolones, and macrolides together amounted to 48% of prescriptions. Common concerns in antimicrobial drug usage included low guidelines compliance and low rate of "access" group antibacterials."

Journal • Gastroenterology • Gynecology • Hematological Disorders • KRAS